<DOC>
	<DOCNO>NCT01066845</DOCNO>
	<brief_summary>To investigate long-term safety effectiveness Adcirca ( tadalafil ) Pulmonary Arterial Hypertension ( PAH ) patient clinical practice －focused topics－ 1 . To evaluate incidence adverse event patient long-term use 2 . To evaluate incidence adverse event decrease blood pressure , bleeding ( include uterine hemorrhage ) , visual disturbance sudden hearing loss .</brief_summary>
	<brief_title>Post Marketing Observational Study Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Patients PAH receive Adcirca Patients meet criteria contraindication patient hypersensitivity tadalafil patient use form organic nitrate patient severe renal impairment patient severe hepatic impairment patient take strong inhibitor CYP3A4 patient take strong inducer CYP3A4</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>